Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Opportunities Provided By Biosimilars

July 20th 2023

Video

Maia Kayal, MD, MS, and Kimberly C. Chen DO, MSHLM, discuss opportunities that biosimilars provide for inflammatory conditions from both a payer and provider perspective.

Savings Potential With Biosimilars

July 20th 2023

Video

Jonathan Kay, MD, and Kimberly C. Chen DO, MSHLM, define what a biosimilar is and discuss the potential for a lower cost than the reference product.

Barriers to Biologics Access

July 20th 2023

Video

Jonathan Kay, MD, reviews the barriers related to access to biologics such as economic barriers, health inequities, or disparities.

Biologics Used in Inflammatory Diseases

July 20th 2023

Video

Maia Kayal, MD, MS, provides an overview of the biologics used in inflammatory diseases.

Cost Drivers Contributing to the Economic Impact of Inflammatory Diseases

July 20th 2023

Video

A panel of experts review the key drivers contributing to the economic impact of inflammatory diseases in the United States.

Humanistic and Economic Impact of Inflammatory Diseases

July 20th 2023

Video

Experts discuss the humanistic and economic impacts that affect patients with inflammatory diseases.

Clinical Overview of Inflammatory Diseases

July 20th 2023

Video

Maia Kayal, MD, MS, and Jonathan Kay, MD, provide a clinical overview of inflammatory diseases and describe comorbid conditions typically seen in patients.

Payer Controls Limiting Semglee Uptake Despite Patient Demand

July 20th 2023

By Laura Joszt, MA

Article

A new analysis finds branded insulin glargine (Lantus) still has a majority of total market volume and new drug starts despite competition from Semglee, an interchangeable biosimilar.

Samsung Bioepis Report Proves Lower Biosimilar Prices Correlate With Greater Market Share

July 19th 2023

By Skylar Jeremias

Article

The second edition of Samsung Bioepis’ Biosimilar Market Report shows strong correlation between biosimilar usage and decreased drug prices, proving that biosimilars are delivering on the promise of savings and price erosion.

Biosimilars Can Expand Treatment Access for Traditionally Excluded Communities

July 18th 2023

By Justina Petrullo

Article

Biosimilars may be able to increase treatment access for traditionally excluded communities, especially racial and ethnic minority populations.